Maker of Wegovy Limits Supply of Obesity Drug in the United States

FRIDAY, May 5, 2023 (HealthDay News) -- Danish drugmaker Novo Nordisk said Thursday it will limit distribution of its low-dose versions of the wildly popular weight-loss drug Wegovy, to ensure that people already taking the drug will have enough supply.
The medication is one of three glucagon-like peptide 1 receptor agonists that are effective for weight loss but have faced shortages amid a boom in sales triggered by celebrity endorsements, the company said in a statement. The two other drugs in this class, Mounjaro (Eli Lilly) and Ozempic (Novo Nordisk), are also used to treat type 2 diabetes. Wegovy is the same medication as Ozempic, but it is available in higher doses.
"Today, we are serving hundreds of thousands of U.S. patients with Wegovy," the company said. "However, trends indicate that demand for Wegovy in the U.S. will exceed our current supply capacity."
While working to expand supply, the drugmaker is sending "limited quantities" of 0.25-mg, 0.5-mg, and 1-mg dose strengths to wholesalers. Those drugs will eventually be distributed to retail pharmacies.
"We anticipate that many patients will have difficulty filling Wegovy prescriptions at these doses through September," the company noted. However, "we do not currently anticipate supply interruptions of the 1.7 mg and 2.4 mg dose strengths of Wegovy."
Related Posts
Moderna Says Omicron-Specific Booster Should Be Ready by August
THURSDAY, June 23, 2022 (HealthDay News) -- Moderna Inc. announced Wednesday...
QOL Advantages in Young Adulthood for Those Conceived Through ART
WEDNESDAY, March 23, 2022 (HealthDay News) -- Being conceived via assisted...
Need a Prostate Exam? Here’s What to Expect
WEDNESDAY, May 31, 2023 (HealthDay News) -- You're due for a prostate exam, but...
Dog Years: New Research Will Track Canine Aging
MONDAY, Feb. 21, 2022 (HealthDay News) -- Joshua Akey admits he didn't care much...